Neuropathological study on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine of the crab-eating monkey

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Acta Neuropathologica

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/BF00687790PMID 3259063
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mitochondrial abnormalities in Menkes' kinky hair disease (MKHD)

  2004cited by this paper
• Electron microscopic studies on pigment granules in the substantia nigra and locus coeruleus of the Japanese monkey (Macaca fuscata yakui)

  2004cited by this paper
• Light- and electron-microscopic studies of intracytoplasmic acidophilic granules in the human locus ceruleus and substantia nigra

  2004cited by this paper
• Long-term effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal dopamine content in young and mature mice.

  1987cited by this paper
• Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+.

  1986cited by this paper
• The effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on presynaptic dopamine uptake sites in the mouse striatum.

  1986cited by this paper
• Locus ceruleus lesions and eosinophilic inclusions in MPTP‐treated monkeys

  1986cited by this paper
• Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP.

  1986cited by this paper
• Normal MPTP binding in parkinsonian substantial nigra: evidence for extraneuronal toxin conversion in human brain.

  1985cited by this paper
• Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity.

  1985cited by this paper
• Primate model of parkinsonism: selective lesion of nigrostriatal neurons by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine produces an extrapyramidal syndrome in rhesus monkeys.

  1985cited by this paper
• Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.

  1985cited by this paper
• Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus.

  1985cited by this paper
• Nucleolar alterations of nerve cells in rats induced by a carcinogen,4-nitroquinoline 1-oxide

  1984cited by this paper
• 1-Methyl-4-phenylpyridinium ion (MPP+): identification of a metabolite of MPTP, a toxin selective to the substantia nigra.

  1984cited by this paper
• Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey.

  1984cited by this paper
• 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset.

  1984cited by this paper
• A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  1983influential reference
• Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.

  1983cited by this paper
• Chronic Parkinsonism secondary to intravenous injection of meperidine analogues.

  1979cited by this paper
• Pigments in the red nucleus and substantia nigra in man and in representative old and new world monkeys.

  1970cited by this paper
• Pigments in the red nucleus and substantia nigra in man and in representative old and new world monkeys.

  1970cited by this paper
• [Electron microscopic study of the pigment granules in the substantia nigra].

  1968cited by this paper
• Pigment, abnormal mitochondria and laminar bodies in human sympathetic neurons

  1967cited by this paper

• Structural Plasticity of GABAergic Pallidothalamic Terminals in MPTP-Treated Parkinsonian Monkeys: A 3D Electron Microscopic Analysis

  2023cites this paper
• Apoptotic factors and mitochondrial complexes assist determination of strain-specific susceptibility of mice to Parkinsonian neurotoxin MPTP

  2022influential citation
• A mutation in protein kinase C-gamma alters SNC neuron morphology and decreases synaptic vesicles in dopaminergic striatal terminals in the AS/AGU rat

  2013cites this paper
• Dark cell change of the cerebellar Purkinje cells induced by terbutaline under transient disruption of the blood–brain barrier in adult rats: morphological evaluation

  2012cites this paper
• Trichloroethylene and Parkinson disease.

  2011cites this paper
• Mitochondrial Dysfunction in Parkinson's Disease

  2010cites this paper
• Chronic intraventricular administration of 1-methyl-4-phenylpyridinium as a progressive model of Parkinson's disease.

  2008cites this paper
• Acute and Chronic Administration of 1-Methyl-4-Phenylpyridinium

  2008cites this paper
• Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice

  2007cites this paper
• Rat model of Parkinson's disease: chronic central delivery of 1-methyl-4-phenylpyridinium (MPP+).

  2006cites this paper
• Mitochondria covered with a net of parallel and latticed filaments in nigral neurons of monkeys with experimental parkinsonism

  2004cites this paper
• Enhanced substantia nigra mitochondrial pathology in human α-synuclein transgenic mice after treatment with MPTP111-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  2004cites this paper
• Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP.

  2004cites this paper
• Specific up‐regulation of GADD153/CHOP in 1‐methyl‐4‐phenyl‐pyridinium‐treated SH‐SY5Y cells

  2002influential citation
• Neurotoxicity of MPTP

  2001cites this paper
• Abnormal mitochondrial morphology in sporadic Parkinson's and Alzheimer's disease cybrid cell lines.

  2000cites this paper
• Acute ultrastructural effects of MPTP on the nigrostriatal pathway of the C57BL/6 adult mouse: Evidence of compensatory plasticity in nigrostriatal neurons

  2000cites this paper
• Orphan neurones and amine excess: the functional neuropathology of Parkinsonism and neuropsychiatric disease.

  1998cites this paper
• Cytotoxic effects of MPTP on SH-SY5Y human neuroblastoma cells.

  1997cites this paper
• Evolution of nerve fiber degeneration in the striatum in the MPTP-treated squirrel monkey

  1994cites this paper
• 2-Methyl-1,2,3,4-tetrahydroisoquinoline does dependently reduce the number of tyrosine hydroxylase-immunoreactive cells in the substantia nigra and locus ceruleus of C57BL/6J mice.

  1994cites this paper
• Search for neurotoxins structurally related to 1-methyl-4-phenylpyridine (MPP+) in the pathogenesis of Parkinson's disease.

  1992cites this paper
• Interactions Between MPTP-Induced and Age-Related Neuronal Death in a Murine Model of Parkinson’s Disease

  1992cites this paper
• Spontaneous recovery of MPTP-damaged catecholamine systems in goldfish brain areas.

  1992cites this paper
• Protective and preventive therapeutic strategies: monoamine oxidase inhibitors.

  1992cites this paper
• Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey.

  1991cites this paper
• Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP.

  1990cites this paper
• Selegiline as neuroprotective therapy in Parkinson's disease: Concepts and controversies

  1990cites this paper
• Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model for parkinsonism.

  1990cites this paper
• MPTP produces reversible disappearance of tyrosine hydroxylase-containing retinal amacrine cells.

  1990cites this paper